MX2017008179A - Proceso para la preparacion de un compuesto de diariltiohidantoina. - Google Patents

Proceso para la preparacion de un compuesto de diariltiohidantoina.

Info

Publication number
MX2017008179A
MX2017008179A MX2017008179A MX2017008179A MX2017008179A MX 2017008179 A MX2017008179 A MX 2017008179A MX 2017008179 A MX2017008179 A MX 2017008179A MX 2017008179 A MX2017008179 A MX 2017008179A MX 2017008179 A MX2017008179 A MX 2017008179A
Authority
MX
Mexico
Prior art keywords
preparation
diarylthiohydantoin compound
compound
diarylthiohydantoin
intermediates
Prior art date
Application number
MX2017008179A
Other languages
English (en)
Inventor
Andras Horvath
Johan Erwin Edmond Weerts
Ben Haim Cyril
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MX2017008179A publication Critical patent/MX2017008179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen los procesos e intermedios para la preparación del compuesto (X), que se investiga actualmente para el tratamiento del cáncer de próstata. (ver Fórmula).
MX2017008179A 2014-12-19 2015-12-17 Proceso para la preparacion de un compuesto de diariltiohidantoina. MX2017008179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19
PCT/US2015/066356 WO2016100652A2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Publications (1)

Publication Number Publication Date
MX2017008179A true MX2017008179A (es) 2017-09-18

Family

ID=55168400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008179A MX2017008179A (es) 2014-12-19 2015-12-17 Proceso para la preparacion de un compuesto de diariltiohidantoina.

Country Status (32)

Country Link
US (1) US9688655B2 (es)
EP (4) EP3233803B1 (es)
JP (2) JP6681902B2 (es)
KR (1) KR102586059B1 (es)
AR (1) AR103228A1 (es)
AU (1) AU2015364537B2 (es)
BR (1) BR112017013113B1 (es)
CA (1) CA2970937A1 (es)
CY (2) CY1121684T1 (es)
DK (3) DK3372585T3 (es)
EA (4) EA201892487A1 (es)
ES (3) ES2827549T3 (es)
HR (3) HRP20220750T1 (es)
HU (2) HUE052475T2 (es)
IL (1) IL252843A0 (es)
LT (3) LT3372584T (es)
MA (1) MA41200B1 (es)
MD (1) MD3233803T2 (es)
ME (1) ME03420B (es)
MX (1) MX2017008179A (es)
NZ (1) NZ732766A (es)
PH (1) PH12017501152A1 (es)
PL (3) PL3372585T3 (es)
PT (3) PT3372584T (es)
RS (3) RS61060B9 (es)
SG (4) SG10201912802XA (es)
SI (3) SI3372585T1 (es)
TR (1) TR201904739T4 (es)
TW (4) TWI703132B (es)
UA (1) UA123201C2 (es)
WO (1) WO2016100652A2 (es)
ZA (1) ZA201704877B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58428B1 (sr) * 2014-12-19 2019-04-30 Aragon Pharmaceuticals Inc Postupci za pripremu jedinjenja diariltiohidantoina
EP3233803B1 (en) * 2014-12-19 2019-01-30 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2007126765A2 (en) 2006-03-27 2007-11-08 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
PE20141375A1 (es) * 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
EA019970B8 (ru) * 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
CA2829322C (en) 2011-03-10 2017-01-10 Suzhou Kintor Pharmaceuticals, Inc. Substituted thioimidazolidinone androgen receptor antagonists and uses thereof
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
KR102144139B1 (ko) * 2012-03-29 2020-08-12 쉰들러, 윌리엄 다이아스피린 가교결합된 페길화 헤모글로빈
EP3020714B1 (en) * 2013-05-29 2022-12-28 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
EP3233803B1 (en) * 2014-12-19 2019-01-30 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound

Also Published As

Publication number Publication date
PL3233803T3 (pl) 2019-07-31
TR201904739T4 (tr) 2019-05-21
TWI703132B (zh) 2020-09-01
SI3372585T1 (sl) 2022-08-31
EP3372584B1 (en) 2020-09-23
SG10201912805SA (en) 2020-02-27
ES2827549T9 (es) 2021-07-02
HUE042409T2 (hu) 2019-06-28
SI3233803T1 (sl) 2019-05-31
EP3372586A1 (en) 2018-09-12
KR20170095976A (ko) 2017-08-23
ES2919951T3 (es) 2022-07-29
MD3233803T2 (ro) 2019-07-31
WO2016100652A3 (en) 2016-08-25
TW201945343A (zh) 2019-12-01
CY1121684T1 (el) 2020-07-31
US9688655B2 (en) 2017-06-27
CN107108507A (zh) 2017-08-29
TWI683810B (zh) 2020-02-01
RS61060B9 (sr) 2021-07-30
HRP20201847T2 (hr) 2021-05-28
AU2015364537A1 (en) 2017-07-06
SG11201704969QA (en) 2017-07-28
DK3372584T5 (da) 2021-05-17
PT3372584T (pt) 2020-11-13
US20160176845A1 (en) 2016-06-23
EP3233803B1 (en) 2019-01-30
CY1123611T1 (el) 2022-03-24
AU2015364537B2 (en) 2020-10-08
PT3372585T (pt) 2022-07-08
ME03420B (me) 2020-01-20
MA41200B1 (fr) 2019-05-31
ES2827549T3 (es) 2021-05-21
BR112017013113B1 (pt) 2023-11-21
EA201892487A1 (ru) 2019-07-31
HRP20220750T1 (hr) 2022-09-02
TW202031639A (zh) 2020-09-01
EP3372585B1 (en) 2022-03-30
EA201892485A1 (ru) 2019-07-31
LT3372585T (lt) 2022-07-11
PT3233803T (pt) 2019-05-20
ES2718539T3 (es) 2019-07-02
EP3233803A2 (en) 2017-10-25
EA201892486A1 (ru) 2019-07-31
HRP20201847T1 (hr) 2021-03-19
HUE052475T2 (hu) 2021-05-28
JP2020114842A (ja) 2020-07-30
NZ732766A (en) 2023-07-28
CA2970937A1 (en) 2016-06-23
DK3372584T3 (da) 2021-01-04
KR102586059B1 (ko) 2023-10-05
UA123201C2 (uk) 2021-03-03
BR112017013113A2 (pt) 2017-12-26
PL3372585T3 (pl) 2022-10-10
RS63455B1 (sr) 2022-08-31
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
LT3233803T (lt) 2019-04-10
EP3372584B9 (en) 2021-03-31
SG10201912811QA (en) 2020-02-27
LT3372584T (lt) 2020-12-10
DK3233803T3 (en) 2019-04-08
TW201639825A (zh) 2016-11-16
HRP20190540T1 (hr) 2019-06-14
TWI689494B (zh) 2020-04-01
JP6681902B2 (ja) 2020-04-15
SG10201912802XA (en) 2020-02-27
EP3372585A1 (en) 2018-09-12
ZA201704877B (en) 2019-02-27
DK3372585T3 (da) 2022-05-30
EP3372584A1 (en) 2018-09-12
RS61060B1 (sr) 2020-12-31
SI3372584T1 (sl) 2021-08-31
RS58454B1 (sr) 2019-04-30
JP2018501237A (ja) 2018-01-18
MA41200A (fr) 2017-10-25
IL252843A0 (en) 2017-08-31
WO2016100652A2 (en) 2016-06-23
JP6903785B2 (ja) 2021-07-14
AR103228A1 (es) 2017-04-26
EA201791390A1 (ru) 2017-10-31
TWI753336B (zh) 2022-01-21
TW201945342A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
PH12017501152A1 (en) Process for the preparation of a diarylthiohydantoin compound
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3423488A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2018136617A3 (en) Bacteria for treating cancer
EP3606531A4 (en) CANCER TREATMENT METHODS
EP3442946A4 (en) METHOD FOR THE TREATMENT OF CANCER
MX2020007742A (es) Procesos para preparar fluorocetolidos.
EP3487999A4 (en) METHODS OF TREATING CANCER
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
EP3723765A4 (en) CANCER TREATMENT METHODS
MX2017002609A (es) Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso.
EP3669279A4 (en) METHOD OF TREATMENT OF CANCER BY INHIBITION OF SETD2
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
EP3592357A4 (en) METHOD OF TREATMENT OF CANCER
EP3442555A4 (en) METHODS OF TREATING BREAST CANCER
EP3407906A4 (en) METHOD FOR THE TARGETED INTRAPROSTATIC ADMINISTRATION OF PRX302 FOR THE TREATMENT OF PROSTATE CANCER
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
AU2016902922A0 (en) Methods of Treating Cancer (I)
AU2016902923A0 (en) Methods of Treating Cancer (II)
EP3125878A4 (en) Methods of treating breast cancer
IN2014CH02021A (es)
AU2014900647A0 (en) Combination method for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration